Palbociclib improves survival in late endometrial cancer: study
AusDoc brings you the latest news from the European Society for Medical Oncology virtual congress 2020.
Palbociclib plus letrozole appears to prolong progression-free survival (PFS) in women with primary stage four or relapsed oestrogen receptor-positive endometrial cancer, Danish researchers say.
Results of the phase 2 study in 77 women were reported at the European Society for Medical Oncology (ESMO) virtual congress 2020.
Prior surgery, radiation therapy, chemotherapy or one line of endocrine therapy